Skip to main content
27 Nov | 2024

We hold the annual meeting of the PROMINENT consortium

Representatives from 18 partner organizations have shared the progress of the project and decided on new actions for the future.

14 Nov | 2024

EMA recommends approval of lecanemab for the treatment of early-stage Alzheimer's disease

EMA approval of lecanemab after a first negative opinion in July of this year

12 Nov | 2024

The SCAP-AD project seeks volunteers to validate new ultra-sensitive diagnostic methods for the early detection of Alzheimer's disease

The BBRC coordinates the neuroimaging work, including the collection, analysis and control of magnetic resonance images.

07 Nov | 2024

Dr. Gemma Salvadó, new Group Leader of the Neuroimaging Research Group at BBRC

Salvadó holds a PhD in Biomedicine from the University of Barcelona and has a solid background in the field of neuroimaging.

04 Nov | 2024

BBRC's outstanding participation at the CTAD 2024 conference

The event programme included six scientific posters on the centre's research.

29 Oct | 2024

We validate centiloid metric as a reliable measure of Alzheimer's-related amyloid plaques

The work, led by the BBRC and published in Alzheimer’s & Dementia, has been pivotal in securing the European Medicines Agency's approval of the Centiloid metric as a valid biomarker for Alzheimer’s disease.

11 Oct | 2024

Having treatments for Alzheimer's is a social emergency

It is crucial to continue research to develop new treatments that are safer and accessible to everyone.

09 Oct | 2024

We develop brain organoids from stem cells to explore the onset and progression of Alzheimer’s

The study, led by Dr. Laura García González, postdoctoral researcher in the Genomics Research Group of the Barcelonaßeta Brain Research Center, analyzes the biological and genetic mechanisms of Alzheimer's disease.